Patents Examined by Dong Jiang
  • Cross-reactive and bispecific anti-IL-17A/F antibodies
    Patent number: 8790642
    Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: July 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu
  • Methods of treatment using anti-IL-17A/IL-17F cross-reactive antibodies
    Patent number: 8771697
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: July 8, 2014
    Assignee: Novimmune SA
    Inventors: Krzysztof Masternak, Olivier Leger
  • Anti-IL-17A/IL-17F cross-reactive antibodies
    Patent number: 8715669
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Novimmune SA
    Inventors: Krzysztof Masternak, Olivier Leger
  • Binding compounds for IL-27
    Patent number: 8691953
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Nucleic acids encoding engineered anti-IL-23R antibodies
    Patent number: 8691532
    Abstract: Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Leonard G. Presta
  • Antibodies specific to IL-17A and IL-17F
    Patent number: 8679494
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: March 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Thomas Allen Ceska, Alistair James Henry
  • Engineered anti-TSLP antibody
    Patent number: 8637019
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Leonard G. Presta
  • Antagonists of IL-6
    Patent number: 8632774
    Abstract: A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: January 21, 2014
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Lynda Misher, Alan Keith Lofquist, Peter Robert Baum, Peter Armstrong Thompson
  • Antibodies binding IL-1 related polypeptides
    Patent number: 8628777
    Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 14, 2014
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Guohua James Pan
  • Nucleic acids encoding antibody molecules which bind IL-17A and IL-17F
    Patent number: 8617847
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: December 31, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Methods of treatment using anti-IL-17F antibodies
    Patent number: 8609093
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: December 17, 2013
    Assignee: Novimmune S. A.
    Inventors: Krzysztof Masternak, Francois Rousseau
  • Antibodies that bind both IL-17A and IL-17F
    Patent number: 8609099
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: December 17, 2013
    Assignee: Zymogenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
  • Antibody molecules which bind IL-17A and IL-17F
    Patent number: 8580265
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: November 12, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Antibody molecules that bind to IL-6 receptor
    Patent number: 8562991
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 22, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Anti-IL-12/IL-23 antibodies
    Patent number: 8563697
    Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: October 22, 2013
    Assignee: Cephalon Australia Pty. Ltd.
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
  • Polynucleotides encoding antibodies that bind both IL-17A and IL-17F
    Patent number: 8557544
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: October 15, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Methods of treatment using IL-18 receptor antigen binding proteins
    Patent number: 8540993
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: September 24, 2013
    Assignee: AMGEN Inc.
    Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Methods of producing anti-IL-22RA antibodies
    Patent number: 8536309
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: September 17, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
  • Methods of reducing inflammation in cardiomyopathy
    Patent number: 8529894
    Abstract: The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: September 10, 2013
    Assignee: Immunex Corporation
    Inventors: Paul B. J. Burton, Theresa A. Deisher
  • IL-17A antibodies
    Patent number: 8519107
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 27, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu